An Early Success

The example outlined demonstrates an early success of the Resonant platform prior to full platform scale-up, where dozens of equal or greater caliber candidates have been generated. Although only a couple of hundred clones were generated in this early run, among these was the high-value candidate RT-00001. This antibody targets a protein specifically expressed in the tumor microenvironment, highly efficacious as a single agent therapeutic, and would not have been discovered by industry standard screening methods.

Microenvironment Specific Effects

RT-00001 is therapeutically active against physiological tumor cells, but not in standard 2D cultures. The target for RT-00001 has been overlooked by standard industry approaches before.

Resonant System

Control

RT-00001

Note the distinctive epithelial-mesenchymal (EMT) physiology in Resonant microenvironment conditions. RT-00001 treatment induces formation of apoptotic bodies.

Standard Industry Approach

Control

RT-00001

Treatment does not affect 2D cultured cells.

Specific Expression in the Tumor State

Tumor tissue biopsy specimens from pancreatic, melanoma, breast, colon, and brain tumors demonstrate widespread RT-00001 target overexpression in these cancer types. Normal tissues from these same sites show little to no RT-00001 staining.

normal breast

breast cancer

normal colon

colorectal cancer

normal pancreas

pancreatic cancer

normal brain

brain cancer

normal skin

melanoma

RT-00001 Dramatically Reduces Metastasis

RT-00001 significantly inhibits MDA-MB-231 metastasis and growth in an in vivo mouse model. Luciferase expressing MDA-MB-231 cells were injected into the left ventricle of nude mice and treated with control ab or RT-00001 twice weekly for 4 weeks.

Efficacy in Patient-Derived Tumors

Model 1: Human triple-negative breast cancer PDX MC-1. Tumors implanted and allowed to establish contacts and vasculature for 7 days prior to initiation of treatment. No signs of toxicity or distress in RT-00001-treated animals.

Model 2: Human triple-negative breast cancer PDX UM-1. This model is relatively slow-growing. Tumor implantation and treatment schedule as at left. No signs of toxicity or distress in RT-00001-treated animals.